[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0609802A2 - composto, composição farmacêutica e uso de um composto - Google Patents

composto, composição farmacêutica e uso de um composto

Info

Publication number
BRPI0609802A2
BRPI0609802A2 BRPI0609802A BRPI0609802A BRPI0609802A2 BR PI0609802 A2 BRPI0609802 A2 BR PI0609802A2 BR PI0609802 A BRPI0609802 A BR PI0609802A BR PI0609802 A BRPI0609802 A BR PI0609802A BR PI0609802 A2 BRPI0609802 A2 BR PI0609802A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI0609802A
Other languages
English (en)
Inventor
Kiely Andrew
G Taveras Arthur
Nolte Bert
Gallagher Brian
Gege Christian
Steeneck Christoph
Richter Frank
Bluhm Harald
Kroth Heiko
Deng Hongbo
Sucholeiki Irving
Van Veldhuizen Joshua
Boer Jurgen
Hochguertel Matthias
Schneider Matthias
Essers Michael
Feurstein Tim
Powers Timothy
Wu Xinyuan
Original Assignee
Alantos Pharmaceuticals Holding Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alantos Pharmaceuticals Holding Inc filed Critical Alantos Pharmaceuticals Holding Inc
Publication of BRPI0609802A2 publication Critical patent/BRPI0609802A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
BRPI0609802A 2005-05-20 2006-05-22 composto, composição farmacêutica e uso de um composto BRPI0609802A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68347005P 2005-05-20 2005-05-20
US70646505P 2005-08-08 2005-08-08
US73499105P 2005-11-09 2005-11-09
PCT/US2006/020970 WO2006128184A2 (en) 2005-05-20 2006-05-22 Pyrimidine or triazine fused bicyclic metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
BRPI0609802A2 true BRPI0609802A2 (pt) 2017-05-02

Family

ID=37239216

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0609802A BRPI0609802A2 (pt) 2005-05-20 2006-05-22 composto, composição farmacêutica e uso de um composto

Country Status (13)

Country Link
US (2) US20060293345A1 (pt)
EP (1) EP1910367A2 (pt)
JP (3) JP5463034B2 (pt)
KR (1) KR20080087070A (pt)
CN (1) CN101238127A (pt)
AU (1) AU2006251989B2 (pt)
BR (1) BRPI0609802A2 (pt)
CA (1) CA2608890C (pt)
CR (1) CR9614A (pt)
EA (1) EA013525B1 (pt)
IL (1) IL187495A0 (pt)
NO (1) NO20076554L (pt)
WO (1) WO2006128184A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US20070155737A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20080176870A1 (en) * 2006-11-20 2008-07-24 Bert Nolte Heterobicyclic metalloprotease inhibitors
AU2007321923A1 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic matrix metalloprotease inhibitors
JP2010520293A (ja) 2007-03-07 2010-06-10 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド 複素環式部分を含有するメタロプロテアーゼ阻害剤
MX2009013136A (es) 2007-06-04 2010-04-30 Techfields Inc Profarmacos de nsaias con piel y membranas con indices de penetracion muy altos y nuevos usos medicinales.
WO2009075790A1 (en) * 2007-12-07 2009-06-18 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors for intra-articular application
KR101649482B1 (ko) 2008-05-05 2016-08-19 사노피 아실아미노-치환된 융합된 사이클로펜탄카복실산 유도체 및 이들의 약제로서의 용도
KR102225999B1 (ko) 2008-12-04 2021-03-10 충시 위 고투과력을 가진 조성물 및 이의 적용
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
CN101709034B (zh) * 2009-12-14 2017-05-31 大连九信精细化工有限公司 双环[2.2.2]辛烷‑1，4‑二羧酸单甲酯的合成方法
WO2011082271A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrimidine compounds
TR201810523T4 (tr) 2010-12-08 2018-08-27 Health Glukoserebrosidaz aktivatörleri olarak ornatımlı pirazolopirimidinler.
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
KR101935868B1 (ko) 2011-12-30 2019-04-03 에스케이이노베이션 주식회사 폴리프로필렌 카보네이트 발포체 조성물 제조방법 및 이로부터 제조된 성형품
KR102309973B1 (ko) 2012-01-18 2021-10-06 테크필즈 파마 코., 엘티디. 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물
PL3486245T3 (pl) 2012-12-07 2021-11-08 Vertex Pharmaceuticals Incorporated 2-amino-n-(piperydyn-1-ylo-pirydyn-3-ylo) pirazolo[1,5alfa]pirymidyno-3-karboksyamid jako inhibitor kinazy atr
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
SG10201902206QA (en) 2014-06-05 2019-04-29 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
RS59054B1 (sr) 2014-06-17 2019-08-30 Vertex Pharma Postupak za lečenje raka korišćenjem kombinacije chk1 i atr inhibitora
CN104326914A (zh) * 2014-11-18 2015-02-04 江苏恒祥化工有限责任公司 一种反式-4-甲酸甲酯环己烷甲酸的制备方法
ES2833028T3 (es) 2014-12-25 2021-06-14 Guangzhou Ribobio Co Ltd Composiciones y métodos para inhibir la expresión de ADAMTS-5 y ADAM17
CN104560997B (zh) * 2014-12-25 2018-05-04 中国科学院广州生物医药与健康研究院 抑制ADAMTS-5和ADAM17基因的siRNA组合物及其应用
MX2018003657A (es) 2015-09-30 2018-04-30 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr).
US10633315B2 (en) 2016-10-19 2020-04-28 Eastman Chemical Company Synthesis of bicyclo[2.2.2]octanes
EP3694831A1 (en) 2017-10-11 2020-08-19 Eastman Chemical Company Synthesis of bicyclo[2.2.2]octane derivatives
CN108558672B (zh) * 2018-06-21 2021-04-30 利尔化学股份有限公司 2-硝基-4-三氟甲基苯甲酸及其异构体的制备方法
CN110950868B (zh) * 2018-09-27 2022-05-13 苏州锐明新药研发有限公司 吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用
US10836899B2 (en) 2018-12-13 2020-11-17 Eastman Chemical Company Polyesters with specified crystallization half-times
CN116283995B (zh) * 2022-09-08 2023-12-29 华中科技大学同济医学院附属同济医院 一种脂酰辅酶a合成酶短链家族成员3的激动剂及其应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497814A (en) * 1982-08-16 1985-02-05 Schering Corporation 2-(Pyridinyl)-1,2,4-triazolo[1,5-a]pyrimidines and derivatives useful in increasing cardiac contractility
JPH0750322B2 (ja) * 1986-06-25 1995-05-31 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方
DE3704203A1 (de) * 1987-02-11 1988-08-25 Boehringer Ingelheim Kg Verwendung von oxochinazolinderivaten bei der behandlung der hyperurikaemie
NZ225383A (en) * 1987-08-07 1990-03-27 Sankei Yakuhin Kk Cephalosporin derivatives and pharmaceutical compositions
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5716964A (en) * 1989-12-04 1998-02-10 G.D. Searle & Co. Tetrazolyl substituted imidazo 1,2-a!pyridinylalkyl compounds for treatment of neurotoxic injury
KR910011852A (ko) * 1989-12-04 1991-08-07 폴 디. 매튜카이티스 신경독 장해 치료용 이미다조[1,2-a]피리디닐알킬 화합물
DE3942357A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh 3-aminopyrazolo-heterocyclen, deren verwendung zur bestimmung von wasserstoffperoxid, wasserstoffperoxid-bildenden systemen, peroxidase, peroxidatisch wirksamen substanzen oder von elektronenreichen aromatischen verbindungen, entsprechende bestimmungsverfahren und hierfuer geeignete mittel
US5955470A (en) * 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
CZ281628B6 (cs) * 1991-07-29 1996-11-13 Warner-Lambert Company Deriváty chinazolinu a farmaceutické přípravky na jejich bázi
AU668691B2 (en) * 1991-08-09 1996-05-16 Nycomed Innovation Ab Use of persistent free-radicals in magnetic resonance imaging
US5302586A (en) * 1991-12-19 1994-04-12 G. D. Searle & Co. Phosphonomethyl-imidazo[1,2-a]pyrimidine-2-carboxylic acid compounds for treatment of neurotoxic injury
FR2687675B1 (fr) * 1992-01-31 1997-04-18 Roussel Uclaf Nouveaux derives bicycliques de la pyridine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
JP2794510B2 (ja) * 1992-03-27 1998-09-10 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US5464843A (en) * 1992-06-23 1995-11-07 G.D. Searle & Co. Imidazo[1,2-a]pyridinyldiacid compounds for cognitive enhancement and for treatment of cognitive disorders and neutrotoxic injury
MX9304801A (es) * 1992-08-06 1997-06-28 Warner Lambert Co 2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales.
DE4327027A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
DE4311460A1 (de) * 1993-04-08 1994-10-13 Boehringer Mannheim Gmbh Verfahren zur kolorimetrischen Bestimmung eines Analyten mittels Benzylalkoholdehydrogenase und einem chromogenen Redoxindikator
DE4311464A1 (de) * 1993-04-08 1994-10-13 Boehringer Mannheim Gmbh Verfahren zur kolorimetrischen Bestimmung eines Analyten mit einer PQQ-abhängigen Dehydrogenase
AU4859596A (en) * 1995-02-15 1996-09-04 Pharmacia & Upjohn Company Imidazo{1,2-a}pyridines for the treatment of cns and cardiac diseases
ATE208778T1 (de) * 1995-05-09 2001-11-15 Basf Ag Pyrazolo- 1,5a)-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
IT1286545B1 (it) * 1996-02-09 1998-07-15 Antonio Guarna Derivati benzo(c) chinolizinici,loro preparazione ed uso come inibitori delle 5-alfa-riduttasi
ZA9710197B (en) * 1996-11-13 1999-05-12 Dow Agrosciences Llc N-arylsulfilimine compounds and their use as catalysts in the preparation of n-arylarylsulfonamide compounds
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6110944A (en) * 1997-03-12 2000-08-29 G. D. Searle & Co. LTA4, hydrolase inhibitors
AU6780398A (en) * 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
ITFI970193A1 (it) * 1997-08-01 1999-02-01 Applied Research Systems Uso di derivati benzo(c) chinolizinici come regolatori della crescita delle piante e composizioni ad uso agricolo che contengono tali
US6013654A (en) * 1997-08-14 2000-01-11 Pharmacia & Upjohn Company Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases
JP3773227B2 (ja) * 1997-10-16 2006-05-10 東京応化工業株式会社 レジスト用剥離液組成物およびこれを用いたレジスト剥離方法
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6319660B1 (en) * 1998-12-28 2001-11-20 Eastman Kodak Company Color photographic element containing speed improving compound
US6190848B1 (en) * 1999-07-21 2001-02-20 Eastman Kodak Company Color photographic element containing ballasted triazole derivative and inhibitor releasing coupler
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
FR2801308B1 (fr) * 1999-11-19 2003-05-09 Oreal COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES
US6461538B2 (en) * 1999-12-16 2002-10-08 Fuji Photo Film Co., Ltd. Production process for indolizine compounds and their use in organic light-emitting devices
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
FR2805539B1 (fr) * 2000-02-25 2005-06-10 Oreal Compositions de teinture des fibres keratiniques contenant des derives d'indolizine et procede de teinture
JP2001348520A (ja) * 2000-04-03 2001-12-18 Fuji Photo Film Co Ltd メチン化合物、固体微粒子分散物、インクジェット用記録液、およびインクジェット記録方法
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
IL152477A0 (en) * 2000-04-28 2003-05-29 Baxter Healthcare Sa 2-acyl indol derivatives and their use as anti-tumour agents
KR20030013475A (ko) * 2000-06-30 2003-02-14 와이어쓰 항암제로서의 치환된 트리아졸로피리미딘
US20020041880A1 (en) * 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
TWI243019B (en) * 2000-08-31 2005-11-11 Basf Ag Process for the preparation of a solid herbicidal formulation
JP2002205992A (ja) * 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
JP2004518651A (ja) * 2000-12-15 2004-06-24 グラクソ　グループ　リミテッド 治療用化合物
DE60236851D1 (en) * 2001-02-14 2010-08-12 Warner Lambert Co Pyrimidinmatrixmetalloproteinaseinhibitoren
PA8539501A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
ES2316546T3 (es) * 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
JP4237497B2 (ja) * 2001-03-30 2009-03-11 スミスクライン ビーチャム コーポレーション ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用
US6756498B2 (en) * 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
CA2448306A1 (en) * 2001-05-30 2002-12-05 Alteon Inc. Method for treating fibrotic diseases or other indications
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US20040116462A1 (en) * 2002-12-12 2004-06-17 Mitsunori Ono Indolizine compounds
DE60205265T2 (de) * 2001-09-13 2006-03-30 Synta Pharmaceuticals Corporation, Lexington 1-glyoxylamidindolizine zur behandlung von krebs
US6740649B2 (en) * 2001-09-17 2004-05-25 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE)
DE10160357A1 (de) * 2001-12-08 2003-06-18 Aventis Pharma Gmbh Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen
KR20040077920A (ko) * 2002-01-31 2004-09-07 다이이찌 세이야꾸 가부시기가이샤 이미다조[1,2-ａ]피리딘 유도체
JP2005530788A (ja) * 2002-05-13 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド フェニル置換イミダゾピリジン類およびフェニル置換ベンズイミダゾール類
MXPA04012245A (es) * 2002-06-04 2005-09-30 Neogenesis Pharmaceuticals Inc Compuestos de pirazolo[1,5a]pirimidina como agentes antivirales.
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
KR101050680B1 (ko) * 2002-11-02 2011-07-21 사노피-아벤티스 도이칠란트 게엠베하 콜라게네이즈의 선택적인 억제를 위한 신규한피리미딘-4,6-디카복스아미드
ES2624353T3 (es) * 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
WO2004052315A2 (en) * 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2004082606A2 (en) * 2003-03-13 2004-09-30 Synta Pharmaceuticals Corp. Fused pyrrole compounds
EP1608369B1 (en) * 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US7235569B2 (en) * 2003-05-02 2007-06-26 Wyeth Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use
US20050096256A1 (en) * 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
AU2004259024B2 (en) * 2003-07-23 2011-06-23 Synta Pharmaceuticals, Corp. Compounds for inflammation and immune-related uses
FR2857966A1 (fr) * 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
US20070155737A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US20070155739A1 (en) * 2005-12-30 2007-07-05 Alantos Pharmaceuticals, Inc. Substituted bis-amide metalloprotease inhibitors

Also Published As

Publication number Publication date
CA2608890A1 (en) 2006-11-30
EP1910367A2 (en) 2008-04-16
US20060293345A1 (en) 2006-12-28
NO20076554L (no) 2008-02-19
AU2006251989A1 (en) 2006-11-30
JP5463034B2 (ja) 2014-04-09
KR20080087070A (ko) 2008-09-30
JP2008540687A (ja) 2008-11-20
JP5391351B2 (ja) 2014-01-15
CR9614A (es) 2008-04-28
EA013525B1 (ru) 2010-06-30
JP2014088396A (ja) 2014-05-15
WO2006128184A2 (en) 2006-11-30
IL187495A0 (en) 2008-02-09
EA200702568A1 (ru) 2008-06-30
CA2608890C (en) 2011-08-02
WO2006128184A3 (en) 2007-03-08
US20080161300A1 (en) 2008-07-03
JP2013181033A (ja) 2013-09-12
CN101238127A (zh) 2008-08-06
AU2006251989B2 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI0614730A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0614162A2 (pt) dermocosmético, e, uso de um composto
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0611025A2 (pt) composto, uso de um composto, e, composição farmacêuticamente aceitável
BRPI0819696A2 (pt) Compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0809977A2 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
RU2398586C3 (ru) Фармацевтическая композиция
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0717699A2 (pt) "composição e seus processos de preparação, uso de uma composição e uso coméstico de uma composição!
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0611748A2 (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 20070163776 DE 21/11/2007.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO DE NO 20080093555, APRESENTADA EM 03/07/2008, EM VIRTUDE DO DISPOSTO NOS ARTS. 219, II, DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA, UMA VEZ QUE A PETICAO DE DEPOSITO FOI ARQUIVADA NA RPI NO 2131, DE 08/11/2011.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: ANULADA A PUBLICACAO 11.6.1 NA RPI 2131 DE 08/11/2011, POR TER SIDO INDEVIDA

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: ANULADA A PUBLICACAO 6.7 NA RPI 2071 DE 14/09/2010, POR TER SIDO INDEVIDA

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B151 Others concerning applications: resolution cancelled [chapter 15.31 patent gazette]
B25B Requested transfer of rights rejected

Owner name: ALANTOS PHARMACEUTICALS HOLDING, INC. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]